XOMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.87 USD | -0.44% |
|
-0.40% | -2.13% |
| Sales 2024 * | 14M 19.16M | Sales 2025 * | 23.57M 32.25M | Capitalization | 288M 395M |
|---|---|---|---|---|---|
| Net income 2024 * | -27M -36.95M | Net income 2025 * | -19M -26M | EV / Sales 2024 * | 20.6 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 12.2 x |
| P/E ratio 2024 * |
-10.4
x | P/E ratio 2025 * |
-14.8
x | Employees | 13 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.58% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.44% | ||
| 1 week | -0.40% | ||
| Current month | -0.45% | ||
| 1 month | -0.32% | ||
| 3 months | -1.39% | ||
| 6 months | +11.47% | ||
| Current year | -2.13% |
1 week
24.87
25.07
1 month
24.8125.09
Current year
24.6125.95
1 year
21.4025.98
3 years
21.4027.57
5 years
21.4027.57
10 years
21.4027.57
| Managers | Title | Age | Since |
|---|---|---|---|
Owen Hughes
CEO | Chief Executive Officer | 49 | 22-12-31 |
Thomas Burns
DFI | Director of Finance/CFO | 50 | 06-08-13 |
Bradley Sitko
CIO | Chief Investment Officer | 43 | 23-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Heather Franklin
BRD | Director/Board Member | 58 | 21-08-05 |
| Chairman | 68 | 10-08-25 | |
Joseph Limber
BRD | Director/Board Member | 71 | 12-12-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.68% | 853 M€ | +0.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 24.87 | -0.44% | 421 |
| 24-05-01 | 24.98 | -0.01% | 343 |
| 24-04-30 | 24.98 | -0.31% | 235 |
| 24-04-29 | 25.06 | +0.36% | 1,210 |
| 24-04-26 | 24.97 | -0.08% | 1,752 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm
More quotes
XOMA Corporation is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
24.78
USD
Average target price
57
USD
Spread / Average Target
+130.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.43% | 104B | |
| +8.96% | 105B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- XOMA Stock
- XOMAP Stock
